Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases

Masayuki Furukawa, Mark Raffeld, Carmen Mateo, Akio Sakamoto, Terry W. Moody, Tetsuhide Ito, David J. Venzon, Jose Serrano, Robert T. Jensen

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: Growth factors, particularly insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) in some nonendocrine and a few endocrine tumors, are thought important in recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas. Experimental Design: IGF-I and IGF-IR expression in gastrinomas from 54 patients with Zollinger-Ellison syndrome were analyzed and correlated with clinical/tumor characteristics. IGF-I and IGF-IR mRNA levels were determined by competitive reverse transcription-PCR. IGF-IR expression, assessed by immunohistochemistry, was done on a subset. Results: IGF-IR mRNA was found in 100% and IGF-I in 89%. IGF-I mRNA expression varied by >254-fold, IGF-IR by 2,670-fold, and the levels correlated in a given tumor. The IGF-IR level was lower in gastrinomas of patients who were rendered disease free and increased levels correlated with tumor growth, aggressiveness, extent, and with liver metastases. Increased IGF-I levels correlated with increased growth, tumor extent, and aggressiveness. Neither IGF-IR nor IGF-I levels correlated with tumor location, size, or its clinical/functional features. The IGF-IR correlated with disease-free survival. IGF-IRβ was found in 31 of 32 tumors (97%) by immunohistochemistry. Conclusions: These results indicate that IGF-I and IGF-IR are expressed in almost all gastrinomas. Furthermore, assessment of IGF-I/IGF-IR expression in gastrinomas may be clinically useful in identifying those patients with more aggressive tumors who might benefit from more aggressive treatment.

Original languageEnglish
Pages (from-to)3233-3242
Number of pages10
JournalClinical Cancer Research
Volume11
Issue number9
DOIs
Publication statusPublished - May 1 2005

Fingerprint

Gastrinoma
IGF Type 1 Receptor
Insulin-Like Growth Factor I
Growth and Development
Neoplasm Metastasis
Neoplasms
Messenger RNA
Growth
Immunohistochemistry
Zollinger-Ellison Syndrome
Neuroendocrine Tumors
Reverse Transcription
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. / Furukawa, Masayuki; Raffeld, Mark; Mateo, Carmen; Sakamoto, Akio; Moody, Terry W.; Ito, Tetsuhide; Venzon, David J.; Serrano, Jose; Jensen, Robert T.

In: Clinical Cancer Research, Vol. 11, No. 9, 01.05.2005, p. 3233-3242.

Research output: Contribution to journalArticle

Furukawa, Masayuki ; Raffeld, Mark ; Mateo, Carmen ; Sakamoto, Akio ; Moody, Terry W. ; Ito, Tetsuhide ; Venzon, David J. ; Serrano, Jose ; Jensen, Robert T. / Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 9. pp. 3233-3242.
@article{61162fa411e44c98a9a89f2c1701f7ce,
title = "Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases",
abstract = "Purpose: Growth factors, particularly insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) in some nonendocrine and a few endocrine tumors, are thought important in recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas. Experimental Design: IGF-I and IGF-IR expression in gastrinomas from 54 patients with Zollinger-Ellison syndrome were analyzed and correlated with clinical/tumor characteristics. IGF-I and IGF-IR mRNA levels were determined by competitive reverse transcription-PCR. IGF-IR expression, assessed by immunohistochemistry, was done on a subset. Results: IGF-IR mRNA was found in 100{\%} and IGF-I in 89{\%}. IGF-I mRNA expression varied by >254-fold, IGF-IR by 2,670-fold, and the levels correlated in a given tumor. The IGF-IR level was lower in gastrinomas of patients who were rendered disease free and increased levels correlated with tumor growth, aggressiveness, extent, and with liver metastases. Increased IGF-I levels correlated with increased growth, tumor extent, and aggressiveness. Neither IGF-IR nor IGF-I levels correlated with tumor location, size, or its clinical/functional features. The IGF-IR correlated with disease-free survival. IGF-IRβ was found in 31 of 32 tumors (97{\%}) by immunohistochemistry. Conclusions: These results indicate that IGF-I and IGF-IR are expressed in almost all gastrinomas. Furthermore, assessment of IGF-I/IGF-IR expression in gastrinomas may be clinically useful in identifying those patients with more aggressive tumors who might benefit from more aggressive treatment.",
author = "Masayuki Furukawa and Mark Raffeld and Carmen Mateo and Akio Sakamoto and Moody, {Terry W.} and Tetsuhide Ito and Venzon, {David J.} and Jose Serrano and Jensen, {Robert T.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-04-1915",
language = "English",
volume = "11",
pages = "3233--3242",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases

AU - Furukawa, Masayuki

AU - Raffeld, Mark

AU - Mateo, Carmen

AU - Sakamoto, Akio

AU - Moody, Terry W.

AU - Ito, Tetsuhide

AU - Venzon, David J.

AU - Serrano, Jose

AU - Jensen, Robert T.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Purpose: Growth factors, particularly insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) in some nonendocrine and a few endocrine tumors, are thought important in recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas. Experimental Design: IGF-I and IGF-IR expression in gastrinomas from 54 patients with Zollinger-Ellison syndrome were analyzed and correlated with clinical/tumor characteristics. IGF-I and IGF-IR mRNA levels were determined by competitive reverse transcription-PCR. IGF-IR expression, assessed by immunohistochemistry, was done on a subset. Results: IGF-IR mRNA was found in 100% and IGF-I in 89%. IGF-I mRNA expression varied by >254-fold, IGF-IR by 2,670-fold, and the levels correlated in a given tumor. The IGF-IR level was lower in gastrinomas of patients who were rendered disease free and increased levels correlated with tumor growth, aggressiveness, extent, and with liver metastases. Increased IGF-I levels correlated with increased growth, tumor extent, and aggressiveness. Neither IGF-IR nor IGF-I levels correlated with tumor location, size, or its clinical/functional features. The IGF-IR correlated with disease-free survival. IGF-IRβ was found in 31 of 32 tumors (97%) by immunohistochemistry. Conclusions: These results indicate that IGF-I and IGF-IR are expressed in almost all gastrinomas. Furthermore, assessment of IGF-I/IGF-IR expression in gastrinomas may be clinically useful in identifying those patients with more aggressive tumors who might benefit from more aggressive treatment.

AB - Purpose: Growth factors, particularly insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) in some nonendocrine and a few endocrine tumors, are thought important in recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas. Experimental Design: IGF-I and IGF-IR expression in gastrinomas from 54 patients with Zollinger-Ellison syndrome were analyzed and correlated with clinical/tumor characteristics. IGF-I and IGF-IR mRNA levels were determined by competitive reverse transcription-PCR. IGF-IR expression, assessed by immunohistochemistry, was done on a subset. Results: IGF-IR mRNA was found in 100% and IGF-I in 89%. IGF-I mRNA expression varied by >254-fold, IGF-IR by 2,670-fold, and the levels correlated in a given tumor. The IGF-IR level was lower in gastrinomas of patients who were rendered disease free and increased levels correlated with tumor growth, aggressiveness, extent, and with liver metastases. Increased IGF-I levels correlated with increased growth, tumor extent, and aggressiveness. Neither IGF-IR nor IGF-I levels correlated with tumor location, size, or its clinical/functional features. The IGF-IR correlated with disease-free survival. IGF-IRβ was found in 31 of 32 tumors (97%) by immunohistochemistry. Conclusions: These results indicate that IGF-I and IGF-IR are expressed in almost all gastrinomas. Furthermore, assessment of IGF-I/IGF-IR expression in gastrinomas may be clinically useful in identifying those patients with more aggressive tumors who might benefit from more aggressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=18244366076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244366076&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1915

DO - 10.1158/1078-0432.CCR-04-1915

M3 - Article

VL - 11

SP - 3233

EP - 3242

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -